JP7236065B1 - トリアジン誘導体を含有する医薬組成物 - Google Patents

トリアジン誘導体を含有する医薬組成物 Download PDF

Info

Publication number
JP7236065B1
JP7236065B1 JP2022565717A JP2022565717A JP7236065B1 JP 7236065 B1 JP7236065 B1 JP 7236065B1 JP 2022565717 A JP2022565717 A JP 2022565717A JP 2022565717 A JP2022565717 A JP 2022565717A JP 7236065 B1 JP7236065 B1 JP 7236065B1
Authority
JP
Japan
Prior art keywords
compound
group
substituted
cov
sars
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022565717A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023054292A1 (https=
JPWO2023054292A5 (https=
Inventor
裕樹 立花
彰太 上原
佑斗 宇納
健二 中原
善之 垰田
幸司 笠松
維子 山津
茂 安藤
圭太 深尾
治謙 登
隆之 黒田
晋輔 鳥羽
健太朗 上村
優樹 丸山
道仁 佐々木
洋文 澤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hokkaido University NUC
Shionogi and Co Ltd
Original Assignee
Hokkaido University NUC
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hokkaido University NUC, Shionogi and Co Ltd filed Critical Hokkaido University NUC
Priority claimed from PCT/JP2022/035803 external-priority patent/WO2023054292A1/ja
Application granted granted Critical
Publication of JP7236065B1 publication Critical patent/JP7236065B1/ja
Publication of JPWO2023054292A1 publication Critical patent/JPWO2023054292A1/ja
Publication of JPWO2023054292A5 publication Critical patent/JPWO2023054292A5/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022565717A 2021-09-28 2022-09-27 トリアジン誘導体を含有する医薬組成物 Active JP7236065B1 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
JP2021157929 2021-09-28
JP2021157929 2021-09-28
JP2021171725 2021-10-20
JP2021171725 2021-10-20
JP2022000723 2022-01-05
JP2022000723 2022-01-05
JP2022015035 2022-02-02
JP2022015035 2022-02-02
JP2022131590 2022-08-22
JP2022131590 2022-08-22
PCT/JP2022/035803 WO2023054292A1 (ja) 2021-09-28 2022-09-27 トリアジン誘導体を含有する医薬組成物

Publications (3)

Publication Number Publication Date
JP7236065B1 true JP7236065B1 (ja) 2023-03-09
JPWO2023054292A1 JPWO2023054292A1 (https=) 2023-04-06
JPWO2023054292A5 JPWO2023054292A5 (https=) 2023-09-06

Family

ID=85476839

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022565717A Active JP7236065B1 (ja) 2021-09-28 2022-09-27 トリアジン誘導体を含有する医薬組成物

Country Status (8)

Country Link
US (1) US20250127788A1 (https=)
EP (1) EP4410292A4 (https=)
JP (1) JP7236065B1 (https=)
KR (1) KR20240082359A (https=)
CN (1) CN119818502A (https=)
AU (1) AU2022353486A1 (https=)
CA (1) CA3233206A1 (https=)
MX (1) MX2024003600A (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7273455B1 (ja) * 2022-01-19 2023-05-15 塩野義製薬株式会社 新型コロナウイルス感染症治療用医薬
WO2024193451A1 (en) * 2023-03-17 2024-09-26 Ascletis BioScience Co., Ltd Triazine derivatives, method of making and method of using thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT4122926T (lt) * 2021-04-14 2025-07-25 Shionogi & Co., Ltd. Triazino dariniai, turintys virusų replikaciją slopinantį poveikį, ir juos apimanti farmacinė kompozicija

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002509140A (ja) * 1998-01-13 2002-03-26 アナディーズ・ファーマスーティカルズ，インコーポレイテッド トリアジン抗ウイルス化合物
WO2019087884A1 (ja) * 2017-10-31 2019-05-09 富士フイルム株式会社 組成物、抗菌組成物、抗ウイルス用組成物、抗ノロウイルス用組成物、スプレー、ワイパー
WO2022138988A1 (ja) * 2021-04-14 2022-06-30 塩野義製薬株式会社 ウイルス増殖阻害作用を有するトリアジン誘導体およびそれらを含有する医薬組成物
WO2022158528A1 (ja) * 2021-01-20 2022-07-28 国立大学法人北海道大学 抗ウイルス剤
WO2022212314A1 (en) * 2021-03-29 2022-10-06 Shireen Nature Company For General Trading, Ltd. Willow extract and its use in treating coronavirus infection, inflammation, and associated medical conditions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2399910T3 (pl) 2009-02-13 2014-09-30 Shionogi & Co Pochodne triazyny jako antagoniści receptora p2x3 i/albo p2x2/3 i kompozycja farmaceutyczna zawierająca je
CN103153968B (zh) 2010-08-10 2016-02-03 盐野义制药株式会社 三唑衍生物及含有其的具有镇痛作用的药物组合物
TW201331188A (zh) 2011-12-15 2013-08-01 Shionogi & Co 經取代之三□衍生物及含有其之醫藥組成物
TWI637949B (zh) 2013-06-14 2018-10-11 塩野義製藥股份有限公司 胺基三衍生物及含有其等之醫藥組合物
PH12021552872A1 (en) 2020-04-05 2022-03-21 Pfizer Compounds and methods for the treatment of covid-19
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002509140A (ja) * 1998-01-13 2002-03-26 アナディーズ・ファーマスーティカルズ，インコーポレイテッド トリアジン抗ウイルス化合物
WO2019087884A1 (ja) * 2017-10-31 2019-05-09 富士フイルム株式会社 組成物、抗菌組成物、抗ウイルス用組成物、抗ノロウイルス用組成物、スプレー、ワイパー
WO2022158528A1 (ja) * 2021-01-20 2022-07-28 国立大学法人北海道大学 抗ウイルス剤
WO2022212314A1 (en) * 2021-03-29 2022-10-06 Shireen Nature Company For General Trading, Ltd. Willow extract and its use in treating coronavirus infection, inflammation, and associated medical conditions
WO2022138988A1 (ja) * 2021-04-14 2022-06-30 塩野義製薬株式会社 ウイルス増殖阻害作用を有するトリアジン誘導体およびそれらを含有する医薬組成物
WO2022138987A1 (ja) * 2021-04-14 2022-06-30 塩野義製薬株式会社 ウイルス増殖阻害作用を有するトリアジン誘導体およびそれらを含有する医薬組成物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7273455B1 (ja) * 2022-01-19 2023-05-15 塩野義製薬株式会社 新型コロナウイルス感染症治療用医薬
WO2024193451A1 (en) * 2023-03-17 2024-09-26 Ascletis BioScience Co., Ltd Triazine derivatives, method of making and method of using thereof

Also Published As

Publication number Publication date
CN119818502A (zh) 2025-04-15
MX2024003600A (es) 2024-04-09
CA3233206A1 (en) 2023-04-06
AU2022353486A1 (en) 2024-05-02
US20250127788A1 (en) 2025-04-24
EP4410292A4 (en) 2025-09-03
KR20240082359A (ko) 2024-06-10
JPWO2023054292A1 (https=) 2023-04-06
EP4410292A1 (en) 2024-08-07

Similar Documents

Publication Publication Date Title
JP7105430B1 (ja) ウイルス増殖阻害作用を有するトリアジン誘導体およびそれらを含有する医薬組成物
WO2023054292A1 (ja) トリアジン誘導体を含有する医薬組成物
JP7253866B1 (ja) トリアジン誘導体を含有する経口投与する製剤
JP7236065B1 (ja) トリアジン誘導体を含有する医薬組成物
WO2023042879A1 (ja) ウイルス増殖阻害活性を有する二環性複素環誘導体およびそれらを含有する医薬組成物
WO2023095860A1 (ja) ３ｃｌプロテアーゼ阻害剤及びｃｏｖｉｄ－１９治療用薬剤を組み合わせることを特徴とするｃｏｖｉｄ－１９治療用医薬
JP7273455B1 (ja) 新型コロナウイルス感染症治療用医薬
WO2023033098A1 (ja) ウイルス増殖阻害活性を有する二環性含窒素複素環誘導体およびそれらを含有する医薬組成物
CN116514734A (zh) 三嗪衍生物的制造方法和含有三嗪衍生物的口服给与的制剂
JP7261529B1 (ja) ウイルス増殖阻害作用を有するトリアジン誘導体の製造方法
CN116782904A (zh) 含有三嗪衍生物的医药组合物
HK40114521A (en) Pharmaceutical composition containing triazine derivative
JP7674711B1 (ja) ウラシル誘導体を含有する医薬組成物
WO2025074997A1 (ja) ウイルス増殖阻害活性を有する縮合複素環誘導体およびそれらを含有する医薬組成物
HK40081541A (en) Triazine derivative having virus propagation inhibitory effect, and pharmaceutical composition containing same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221026

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221026

A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A801

Effective date: 20221026

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20221026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221028

A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A80

Effective date: 20221028

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230214

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230214

R150 Certificate of patent or registration of utility model

Ref document number: 7236065

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250